385 related articles for article (PubMed ID: 23929090)
1. Serum uric acid levels and long-term outcomes in chronic kidney disease.
Miyaoka T; Mochizuki T; Takei T; Tsuchiya K; Nitta K
Heart Vessels; 2014 Jul; 29(4):504-12. PubMed ID: 23929090
[TBL] [Abstract][Full Text] [Related]
2. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
3. Uric acid and long-term outcomes in CKD.
Madero M; Sarnak MJ; Wang X; Greene T; Beck GJ; Kusek JW; Collins AJ; Levey AS; Menon V
Am J Kidney Dis; 2009 May; 53(5):796-803. PubMed ID: 19303683
[TBL] [Abstract][Full Text] [Related]
4. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.
Srivastava A; Kaze AD; McMullan CJ; Isakova T; Waikar SS
Am J Kidney Dis; 2018 Mar; 71(3):362-370. PubMed ID: 29132945
[TBL] [Abstract][Full Text] [Related]
5. Impact of Uric Acid Levels on Kidney Disease Progression.
Rincon-Choles H; Jolly SE; Arrigain S; Konig V; Schold JD; Nakhoul G; Navaneethan SD; Nally JV; Rothberg MB
Am J Nephrol; 2017; 46(4):315-322. PubMed ID: 29032376
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
[TBL] [Abstract][Full Text] [Related]
8. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
9. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
[TBL] [Abstract][Full Text] [Related]
10. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
11. Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
Kalil RS; Carpenter MA; Ivanova A; Gravens-Mueller L; John AA; Weir MR; Pesavento T; Bostom AG; Pfeffer MA; Hunsicker LG
Am J Kidney Dis; 2017 Dec; 70(6):762-769. PubMed ID: 28801121
[TBL] [Abstract][Full Text] [Related]
12. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Goicoechea M; de Vinuesa SG; Verdalles U; Ruiz-Caro C; Ampuero J; Rincón A; Arroyo D; Luño J
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1388-93. PubMed ID: 20538833
[TBL] [Abstract][Full Text] [Related]
13. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
14. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.
Málek F; Ošťádal P; Pařenica J; Jarkovský J; Vítovec J; Widimský P; Linhart A; Fedorco M; Coufal Z; Miklík R; Krűger A; Vondraková D; Špinar J
J Crit Care; 2012 Dec; 27(6):737.e11-24. PubMed ID: 22699032
[TBL] [Abstract][Full Text] [Related]
15. J-shaped mortality relationship for uric acid in CKD.
Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
[TBL] [Abstract][Full Text] [Related]
17. Association of serum uric acid with all-cause and cardiovascular mortality in chronic kidney disease stages 3-5.
Yuan J; Zhao J; Qin Y; Xing Y; Yu Z; Zhang Y; Wu H; Zheng Q; Hui Y; Guo S; Wang A; Han M; Ning X; Sun S
Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1518-1527. PubMed ID: 38508991
[TBL] [Abstract][Full Text] [Related]
18. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Levy G; Shi JM; Cheetham TC; Rashid N
Perm J; 2018; 22():17-142. PubMed ID: 30201087
[TBL] [Abstract][Full Text] [Related]
19. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
